categories: CD and Related Antigens (Human)

Mouse Monoclonal to CD25 / IL-2R alpha chain

MEM-181 (IgG1)

Product No.	Form	Quantity	Price
11-218-C025	purified	0.025 mg	choose region
11-218-C100	purified	0.1 mg	choose region
1B-218-C025	biotin	0.025 mg	choose region
1B-218-C100	biotin	0.1 mg	choose region
PB-218-T025	Pacific Blue™	25 tests	choose region
PB-218-T100	Pacific Blue™	100 tests	choose region
1F-218-T025	FITC	25 tests	choose region
1F-218-T100	FITC	100 tests	choose region
1P-218-T025	PE	25 tests	choose region
1P-218-T100	PE	100 tests	choose region
1A-218-T025	APC	25 tests	choose region
1A-218-T100	APC	100 tests	choose region
PC-218-T025	PerCP	25 tests	choose region
PC-218-T100	PerCP	100 tests	choose region
T9-218-T025	PerCP-Cy™5.5	25 tests	choose region
T9-218-T100	PerCP-Cy™5.5	100 tests	choose region
A7-218-T025	Alexa Fluor® 700	25 tests	choose region
A7-218-T100	Alexa Fluor® 700	100 tests	choose region

- In stock! Ready for immediate despatch

- Manufacture on order

Background

CD25 (IL2Ralpha, Tac) is a ligand-binding alpha subunit of interleukin 2 receptor (IL2R). Together with beta and gamma subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas.

Entrez Gene: 10p15-p14

Specificity

The antibody MEM-181 reacts with CD25 (Interleukin-2 receptor alpha chain), a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes.
HLDA VI; WS Code NL N-L024

Immunogen

PHA-activated peripheral blood leucocytes

Species Reactivity: Human Negative Species:	Applications: Flow Cytometry Recommended dilution:2 μg/ml Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.	General references Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro. Pathology. 1991 Jul;23(3):224-8. [Abstract] Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res Immunol. 1992 Jan;143(1):33-7. [Abstract] Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14. [Abstract] [Full Text] Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct;28(10):1319-25. [Abstract] Product Specific References Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997). Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May;19(5):675-84. [Abstract] [Full Text]

Species Reactivity:

Human

Negative Species:

Applications:

Flow Cytometry
Recommended dilution:2 μg/ml

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

General references

*Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin 2 receptor expression in activated T-lymphocytes in vitro. Pathology. 1991 Jul;23(3):224-8. [Abstract]

*Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75). Res Immunol. 1992 Jan;143(1):33-7. [Abstract]

*Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14. [Abstract] [Full Text]

*Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct;28(10):1319-25. [Abstract]

Product Specific References

*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).

*Drbal K, Moertelmaier M, Holzhauser C, Muhammad A, Fuertbauer E, Howorka S, Hinterberger M, Stockinger H, Schütz GJ: Single-molecule microscopy reveals heterogeneous dynamics of lipid raft components upon TCR engagement. Int Immunol. 2007 May;19(5):675-84. [Abstract] [Full Text]

For research use only. Not for drug, diagnostic or other use.

Related Products

Mouse IgG1 Isotype Control

Example Data

Fig. 1. Flow Cytometry analysis

Fig. 1. Surface staining of human PBMC with anti-human CD25 (MEM-181) FITC.
The mononuclear cells were isolated from human peripheral blood, devided in aliquots for duplicate analysis and stimulated with PHA for 2 days.
Panel A, C – staining with anti-human CD25 (MEM-181)
Panel B, D – staining with a standard anti-CD25 monoclonal antibody

PRODUCTS